14 completed, 2 unknown. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 14, Unknown 2 |
Follow Encephalitis, Tick-Borne: new trials by email Literature Review of Encephalitis, Tick-Borne trials Research Report on Encephalitis, Tick-Borne
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Primary TBE Vaccination for the Elderly FSME-IMMUN Vaccine - Tick-borne Encephalitis, Vaccine | Phase 4 | Unknown | Region Örebro County | 90 | 2024-01-01 | 2023-11-18 |
| Application of a TBE-Vaccine in Obese Persons FSME-IMMUN Vaccine - Tick Borne Encephalitis | Phase 4 | Unknown | Medical University of Vienna | 73 | 2015-04-15 | 2019-09-10 |
| Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac TicoVac - Tick-Borne Encephalitis | Phase 4 | Completed | University of Surrey | 40 | 2012-10-01 | 2018-08-03 |
| TBE Seropersistence up to 10 Years After First Booster in Adults FSME-IMMUN 0.5 ml - Tick-borne Encephalitis (TBE) | Phase 4 | Completed | Pfizer | 243 | 2012-04-01 | 2021-01-22 |
| Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Blood draw - Tick Borne Encephalitis, Virus Diseases | Phase 4 | Completed | GlaxoSmithKline | 206 | 2012-03-08 | 2021-08-12 |
| An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Serology blood draw - Tick Borne Encephalitis (TBE) | Phase 4 | Completed | Novartis Vaccines | 126 | 2009-05-01 | 2011-12-08 |
| Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL) - Encephalitis, Tick-Borne | Phase 4 | Completed | Pfizer | 179 | 2009-04-26 | 2018-12-17 |
| Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination TBE vaccination and influenza vaccination - Tick-borne Encephalitis | Phase 4 | Completed | Medical University of Vienna | 67 | 2008-12-01 | 2011-07-22 |
| TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) - Encephalitis, Tick-Borne | Phase 4 | Completed | Pfizer | 314 | 2007-07-01 | 2015-05-21 |
| Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years blood draw - Encephalitis, Tick-Borne | Phase 4 | Completed | Novartis | 235 | 2007-02-01 | 2008-04-23 |
| Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Tick-Borne Encephalitis vaccine - Encephalitis, Tick-Borne | Phase 4 | Completed | Novartis | 179 | 2006-02-01 | 2007-03-13 |
| Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl - Encephalitis, Tick-borne | Phase 4 | Completed | Pfizer | 2005-05-01 | 2015-05-21 | |
| TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) - Encephalitis, Tick-Borne | Phase 4 | Completed | Pfizer | 375 | 2005-05-01 | 2015-05-21 |
| Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Tick-Borne Encephalitis vaccine - Encephalitis, Tick-Borne | Phase 4 | Completed | Novartis | 300 | 2005-03-01 | 2008-03-17 |
| Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years FSME-IMMUN 0.5ml - Tick-borne Encephalitis | Phase 4 | Completed | Pfizer | 340 | 2004-06-01 | 2015-05-21 |
| Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) - Encephalitis, Tick-borne | Phase 4 | Completed | Pfizer | 2004-03-01 | 2015-05-21 |
Virus Diseases (1)
Arbovirus Infections (16) · Brain Diseases (16) · Central Nervous System Diseases (16) · Central Nervous System Infections (16) · Central Nervous System Viral Diseases (16) · Encephalitis (16) · Encephalitis, Arbovirus (16) · Encephalitis, Viral (16) · Flaviviridae Infections (16) · Flavivirus Infections (16) · Infections (16) · Infectious Encephalitis (16) · Nervous System Diseases (16) · Neuroinflammatory Diseases (16) · RNA Virus Infections (16)
Vaccines (3) · Blood Specimen Collection (2) · FSME-IMMUN vaccine (2) · Influenza Vaccines (1)
Pfizer (7) · Novartis (3) · Medical University of Vienna (2) · GlaxoSmithKline (1) · Novartis Vaccines (1) · Region Örebro County (1) · University of Surrey (1)
Germany (6) · Poland (5) · Austria (4) · Belgium (2) · Czechia (1) · Sweden (1) · United Kingdom (1)
Ryszard Konior, MD (2) · Ursula Wiedermann-Schmidt, MD, PhD (2) · David JM Lewis (1)
PMID 21592984, PMID 28545923, PMID 25728316, PMID 30928173, PMID 32528467
2009 (1)